Description

S961 acetate is an high-affinity and selective insulin receptor (IR) antagonist with IC50s of 0.048, 0.027, and 630 nM for HIR-A, HIR-B, and human insulin-like growth factor I receptor (HIGF-IR) in SPA-assay, respectively[1].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)–Metabolism-protein/nucleotide metabolism–C211H295N55O71S2.xC2H4O2—Bioconjug Chem. 2022 May 18;33(5):892-906.|Neuropharmacology. 2023 Jun 30;109649.|J Womens Health Dev. 2023;6(2):56-67.|Neural Regen Res. 2021;16:2465-74.-[1]Schäffer L, et al. A novel high-affinity peptide antagonist to the insulin receptor. Biochem Biophys Res Commun. 2008 Nov 14;376(2):380-3.—-4802.12 (free acid)–99.55–O=C(N[C@@H](CO)C(N[C@@H](CC(C)C)C(N[C@@H](CC(O)=O)C(N[C@@H](CCC(O)=O)C(N[C@@H](CO)C(N[C@@H](CC1=CC=CC=C1)C(N[C@@H](CC2=CC=C(C=C2)O)C(N[C@@H](CC(O)=O)C(N[C@@H](CC3=CNC4=CC=CC=C34)C(N[C@@H](CC5=CC=CC=C5)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCC(N)=O)C(N[C@@H](CC(C)C)C(NCC(NCC(NCC(N[C@@H](CO)C(NCC(NCC(N[C@@H](CO)C(N[C@@H](CO)C(N[C@@H](CC(C)C)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC6=CNC7=CC=CC=C67)C(N[C@@H](C)C(N[C@@H](CCC(N)=O)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CCC(N)=O)C(N[C@@H](CSSC[C@@H](C(N8[C@@H](CCC8)C(N[C@@H](CO)C(N[C@@H](CC9=CC=C(C=C9)O)C(O)=O)=O)=O)=O)NC=O)C(N[C@@H](CCC(O)=O)C(N[C@@H](C(C)C)C(N[C@@H](CC=CNC=CC=CC=C)C(NCC(N[C@@H](CCCNC(N)=N)C(NC)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)CN.O=C(O)C–Metabolic Disease–DMSO : 12.5 mg/mL (ultrasonic)|H2O : 1.79 mg/mL (ultrasonic;adjust pH to 8 with NaOH)–Insulin Receptor—-Protein Tyrosine Kinase/RTK–Peptides